A Phase I Open-label Study of the Safety and Immunogenicity of Escalating Doses of Lipovaxin-MM, a Novel Melanoma Immunotherapeutic, in Patients With Metastatic Melanoma.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Melanoma vaccine (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- 10 Apr 2012 Actual patient number is 12 according to ClinicalTrials.gov.
- 10 Apr 2012 Last checked against ClinicalTrials.gov record.
- 10 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.